Antivirales de acción directa contra la hepatitis C: revisión narrativa
DOI:
https://doi.org/10.59093/27112330.109Palabras clave:
hepatitis c, antivirales, respuesta viral sostenida, genotipo, reacciones adversas, resistencia medicamentosa.Resumen
Desde los años ochenta se ha explorado el tratamiento para el virus de la hepatitis C, aunque en ese entonces los medicamentos disponibles eran poco toleradas y poco eficaces. En el 2011, la introducción de antivirales de acción directa transformó significativamente el curso de la enfermedad, logrando tasas de curación superiores al 90 % en los pacientes. Este avance ha permitido prevenir complicaciones futuras con efectos adversos mínimos. La presente revisión aborda la línea de tiempo del descubrimiento de los antivirales, su mecanismo de acción, sus indicaciones y potencial impacto en la salud pública.
Descargas
Referencias bibliográficas
World Health Organization. Hepatitis C. Fact sheets. Ginebra, Suiza:WHO; 2023. Disponible en https://www.who.int/news-room/fact-sheets/detail/hepatitis-c.
Terrault NA, Francoz C, Berenguer M, Charlton M, Heimbach J. Liver transplantation 2023: Status report, current and future challenges. Clin Gastroenterol Hepatol 2023;21:2150-2166. https://doi.org/10.1016/j.cgh.2023.04.005.
Strader DB, Seeff LB. A brief history of the treatment of viral hepatitis C. Clin Liver 2012;1:6-11. https://doi.org/10.1002/cld.1.
Centers for Disease Control and Prevention (CDC). Hepatitis C surveillance. Atlanta, Georgia, Estados Unidos:CDC;2020. Disponible en https://www.cdc.gov/hepatitis/statistics/2020surveillance/hepatitis-c.htm.
Feldman M, Friedman LS, Brandt LJ. Sleisenger and fordtrans gastrointestinal and liver disease. 11 th edition, Philadelphia: Saunders Elsevier; 2020.
Prince AM, Brotman B, Grady GF et al. Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus. Lancet 1974;2:241-246. https://doi.org/10.1016/s0140-6736(74)91412-3.
Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 1975;292:767-770. https://doi.org/10.1056/NEJM197504102921502.
Morales-Domínguez CA. Antivirales de acción directa en el tratamiento de la hepatitis C crónica: efectividad vs. resistencia [trabajo de grado]. Sevilla, España: Universidad de Sevilla; 2019. Disponible en https://idus.us.es/handle/11441/92264.
Dusheiko G. Side effects of α interferon in chronic hepatitis C. Hepatology 1997;26: 112S-121S. https://doi.org/10.1002/hep.510260720.
Manns MP, Maasoumy B. Breakthroughs in hepatitis C research: From discovery to cure. Nat Rev Gastroenterol Hepatol 2022;19:533-550. https://doi.org/10.1038/s41575-022-00608-8.
McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492. https://doi.org/10.1056/NEJM199811193392101.
Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998;351:83-87. https://doi.org/10.1016/s0140-6736(97)06088-1.
Poordad F, McCone J Jr, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206. https://doi.org/10.1056/NEJMoa1010494.
Dietz C, Maasoumy B. Direct-acting antiviral agents for hepatitis C virus infection-from drug discovery to successful implementation in clinical practice. Viruses 2022;14:1325. https://doi.org/10.3390/v14061325.
Foster GR, Hézode C, Bronowicki JP et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011;141:881-889.e1. https://doi.org/10.1053/j.gastro.2011.05.046.
Maasoumy B, Port K, Markova AA et al. Eligibility and safety of triple therapy for hepatitis C: Lessons learned from the first experience in a real world setting. PLoS One 2013;8:e55285. https://doi.org/10.1371/journal.pone.0055285.
Agut H. Antivirales (a excepción del virus de la inmunodeficiencia humana y la hepatitis). EMC-Tratado de Medicina 2022;26:1-10. https://doi.org/10.1016/S1636-5410(22)46453-1.
Molano J, Cáez CM. Medicamentos disponibles para tratamiento de infección por virus de la hepatitis C. Rev Col Gastroenterol 2012; 27:21-25. http://www.scielo.org.co/pdf/rcg/v27s2/v27s2a06.pdf.
Dueñas-Carrera S, Acosta-Rivero N, Morales-Grillo J et al. Biología molecular del virus de la hepatitis C. Med Interna Méx 2018;34:435-442. https://doi.org/10.24245/mim.v34i3.1903. Opin Pharmacol 2016;30:151-157. https://doi.org/10.1016/j.coph.2016.07.014.
Dubuisson J, Cosset FL. Virology and cell biology of the hepatitis C virus life cycle: An update. J Hepatol 2014;61:S3-S13. https://doi.org/10.1016/j.jhep.2014.06.031.
Gao M, O'Boyle DR, Roberts S. HCV NS5A replication complex inhibitors. Curr Opin Pharmacol 2016;30:151-157. https://doi.org/10.1016/j.coph.2016.07.014.
Shah N, Pierce T, Kowdley KV. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2013;22:1107-1121. https://doi.org/10.1517/13543784.2013.806482.
Bhattacharya D, Aronsohn A, Price J, Lo Re V. Hepatitis C. Guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Disponible en https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciad319/7179952?login=false.
Shah ND, Fried MW. Opciones terapéuticas para los pacientes con hepatitis C crónica y fracaso terapéutico previo. Clin Liver Dis 2016;8:S25-S29. https://doi.org/10.1002/cld.594.
Liu-Young G, Kozal MJ. Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care STDS 2008;22:449-457. https://doi.org/10.1089/apc.2007.0199.
PubChem, National Library of Medicine (US), National Center for Biotechnology Information. PubChem Compound Summary for CID 10324367, Boceprevir;2024. Disponible en https://pubchem.ncbi.nlm.nih.gov/compound/Boceprevir.
Suwanthawornkul T, Anothaisintawee T, Sobhonslidsuk A, Thakkinstian A, Teerawattananon Y. Efficacy of second generation direct-acting antiviral agents for treatment naïve hepatitis C genotype 1: A systematic review and network meta-analysis. PLoS One 2015;10:e0145953. https://doi.org/10.1371/journal.pone.0145953.
Ahmed A, Felmlee DJ. Mechanisms of hepatitis C viral resistance to direct acting antivirals. Viruses 2015;7:6716-6729. https://doi.org/10.3390/v7122968.
Izquierdo L, Helle F, Francois C, Castelain S, Duverlie G, Brochot E. Simeprevir for the treatment of hepatitis C virus infection. Pharmgenomics Pers Med 2014;7:241-249. https://doi.org/10.2147/PGPM.S52715.eCollection2014.
Gane E, Poordad F, Zadeikis N, Valdes J et al. Safety and pharmacokinetics of glecaprevir/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infections and compensated liver disease. Clin Infect Dis 2019;69:1657-1664. https://doi.org/10.1093/cid/ciz022.
Ng TI, Tripathi R, Reisch T et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3/4A protease inhibitor glecaprevir. Antimicrob Agents Chemother 2017;62:e01620-17. https://doi.org/10.1128/AAC.01620-17.
Vivancos MJ, Moreno A, Quereda C. Tratamiento del virus de la hepatitis C con antivirales de acción directa: aspectos prácticos y situación actual. Rev Clin Esp 2018;218:29-37. https://doi.org/10.1016/j.rce.2017.07.006.
Gane EJ, Stedman CA, Hyland RH et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014;146:736-743.e1. https://doi.org/10.1053/j.gastro.2013.11.007.
Balatow P, Sandlin A, Cory TJ. An evaluation of ledipasvir + sofosbuvir for the treatment of chronic hepatitis C infection. Expert Opin Pharmacother 2021;22:1839-1846. https://doi.org/10.1080/14656566.2021.1943359.
Gritsenko D, Hughes G. Ledipasvir/Sofosbuvir (harvoni): Improving options for hepatitis C virus infection. PT. 2015;40:256-276.
Loo N, Lawitz E, Alkhouri N et al. Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients. World J Gastroenterol 2019;25:2229-2239. https://doi.org/10.3748/wjg.v25.i18.2229.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Daclatasvir. In: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD):NIDDK; 2022. Disponible en https://www.ncbi.nlm.nih.gov/books/NBK547875/.
Smith MA, Regal RE, Mohammad RA. Daclatasvir: A NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother 2016;50:39-46. https://doi.org/10.1177/1060028015610342.
Fridell RA, Wang C, Sun JH et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: In vitro and in vivo correlations. Hepatology 2011;54:1924-1935. https://doi.org/10.1002/hep.24594.
Wang SJ, Huang CF, Yu ML. Elbasvir and grazoprevir for the treatment of hepatitis C. Expert Rev Anti Infect Ther 2021;19:1071-1081. https://doi.org/10.1080/14787210.2021.1874351.
Roth D, Nelson DR, Bruchfeld A et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): A combination phase 3 study. Lancet 2015;386:1537-1545. https://doi.org/10.1016/S0140-6736(15)00349-9.
Ahmed R, Kareem R, Venkatesan N et al. Sofosbuvir/Velpatasvir - A promising treatment for chronic hepatitis C virus infection. Cureus 2021;13:e17237. https://doi.org/10.7759/cureus.17237.
Australian Prescriber. Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C. Aust Prescr. 2019;42:108-109. https://doi.org/10.18773/austprescr.2019.033.
Cotter TG, Jensen DM. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: Design, development, and place in therapy. Drug Des Devel Ther 2019;13:2565-2577. https://doi.org/10.2147/DDDT.S17251.
Zeuzem S, Foster GR, Wang S et al. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 2018;378:354-369. https://doi.org/10.1056/NEJMoa1702417.
Rockstroh JK, Lacombe K, Viani RM et al. Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: The EXPEDITION-2 study. Clin Infect Dis 2018;67:1010-1017. https://doi.org/10.1093/cid/ciy220.
Sharafi H, Alavian SM. Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem? World J Hepatol 2018;10:543-548. https://doi.org/10.4254/wjh.v10.i9.543.
Hesamizadeh K, Sharafi H, Rezaee-Zavareh MS, Behnava B, Alavian SM. Next steps toward eradication of hepatitis C in the era of direct acting antivirals. Hepat Mon 2016;16:e37089. https://doi.org/10.5812/hepatmon.37089.
Martinello M, Solomon SS, Terrault NA et al. Hepatitis C. Lancet 2023;402:1085-1096. https://doi.org/10.1016/S0140-6736(23)01320-X.
Lazarus JV, Picchio CA, Byrne CJ et al. A global systematic review of hepatitis C elimination efforts through micro-elimination. Semin Liver Dis 2022;42:159-172. https://doi.org/10.1055/a-1777-6112.
Bhattacharya D, Aronsohn A, Price J, Lo Re V. AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2023 Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis 2023; May 25:ciad319. https://doi.org/10.1093/cid/ciad319.
Alghamdi AS, Alghamdi H, Alserehi HA et al. SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024. Saudi J Gastroenterol 2024;30:S1-S42. https://doi.org/10.4103/sjg.sjg_333_23.
Andrieux-Meyer I, Tan SS, Thanprasertsuk S et al. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): Interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial. Lancet Gastroenterol Hepatol 2021;6:448-458. https://doi.org/10.1016/S2468-1253(21)00031-5.
Bhattacharya D, Belperio PS, Shahoumian TA, Loomis TP, Goetz MB, Mole LA, Backus LI. Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus/hepatitis C virus genotype 1-coinfected patients treated in routine practice. Clin Infect Dis 2017;64:1711-1720. https://doi.org/10.1093/cid/cix111.
Bourlière M, Gordon SC, Flamm SL et al. POLARIS-1 and POLARIS-4 investigators. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 2017; 376:2134-2146.
Rockstroh JK, Lacombe K, Viani RM et al. Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: The EXPEDITION-2 study. Clin Infect Dis 2018;67:1010-1017. https://doi.org/10.1093/cid/ciy220.
Society for Maternal-Fetal Medicine (SMFM), Dotters-Katz SK, Kuller JA, Hughes BL. Society for maternal-fetal medicine consult series #56: Hepatitis C in pregnancy-updated guidelines. Am J Obstet Gynecol 2021;225:B8-B18. https://doi.org/10.1016/j.ajog.2021.06.008.
Fehily SR, Papaluca T, Thompson AJ. Long-term impact of direct-acting antiviral agent therapy in HCV cirrhosis: Critical review. Semin Liver Dis 2019;39:341-353. https://doi.org/10.1055/s-0039-1685538.
World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Ginebra, Suiza:WHO; 2023. Disponible en https://www.who.int/publications/i/item/WHO-HIV-2016.06.
Dore GJ, Bajis S. Hepatitis C virus elimination: Laying the foundation for achieving 2030 targets. Nat Rev Gastroenterol Hepatol 2020;18:91-92. https://doi.org/10.1038/s41575-020-00392-3.
Waked I, Esmat G, Elsharkawy A et al. Screening and treatment program to eliminate hepatitis C in Egypt. N Engl J Med 2020;382:1166-1174. https://doi.org/10.1056/NEJMsr1912628.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2024 Hepatología
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
La política de reconocimiento de autoría de Hepatología se basa en los criterios indicados por el ICMJE para conferir crédito de un trabajo a una persona, a la vez que se le atribuye responsabilidad por la publicación del mismo.
| Estadísticas de artículo | |
|---|---|
| Vistas de resúmenes | |
| Vistas de PDF | |
| Descargas de PDF | |
| Vistas de HTML | |
| Otras vistas | |
